Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06640166CT.gov Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. | — | Recruiting | — | — | — |
NCT05722327CT.gov Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT05710406CT.gov Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer | — | Active Not Recruiting | — | — | — |
NCT06322147CT.gov Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer | — | Unknown | — | — | — |
NCT05308446CT.gov Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation | — | Active Not Recruiting | — | — | — |
NCT05040568CT.gov A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD) | — | Completed | — | — | — |
NCT04616183CT.gov LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT03803553CT.gov Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | — | Recruiting | — | — | — |
NCT03774680CT.gov Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer | — | Unknown | — | — | — |
NCT03446157CT.gov Palbociclib and Cetuximab in Metastatic Colorectal Cancer | — | Completed | — | — | — |
Show 22 more trialsShow fewer
NCT03365882CT.gov S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT01217450CT.gov Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors | — | Completed | — | — | — |
NCT01254617CT.gov Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer | — | Completed | — | — | — |
NCT01294826CT.gov Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT01287130CT.gov AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer | — | Completed | — | — | — |
NCT01198535CT.gov Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT00835679CT.gov Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery | — | Terminated | — | — | — |
NCT00766220CT.gov Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver | — | Withdrawn | — | — | — |
NCT01126450CT.gov Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT00845039CT.gov A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab | — | Terminated | — | — | — |
NCT01637194CT.gov Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer | — | Completed | — | — | — |
NCT00551421CT.gov Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00494611CT.gov A Study of the Perioperative Use of Cetuximab in Colon Cancer Patients | — | Terminated | — | — | — |
NCT00499369CT.gov Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy | — | Terminated | — | — | — |
NCT00397384CT.gov Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | — | Completed | — | — | — |
NCT00336856CT.gov Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy | — | Completed | — | — | — |
NCT00193219CT.gov Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00134069CT.gov Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00101348CT.gov Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00100841CT.gov Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer | — | Completed | — | — | — |
NCT00079274CT.gov Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer | — | Completed | — | — | — |
NCT00077298CT.gov Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colon Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cetuximab (this asset) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P3 | B · 62 |
| Floxuridine | City of Hope Medical Center | P2 | BBB |
| Fluorouracilum | Akeso | P4 | BB |
| Oxaliplatin | Sun Yat-sen University | P3 | BB |
| Pertuzumab | IFOM ETS - The AIRC Institute of Molecular Oncology | P3 | BB |
| Palbociclib | Lebanese University | P2 | BB |
| Trastuzumab | IFOM ETS - The AIRC Institute of Molecular Oncology | P3 | BB |
| Irinotecan | SCRI Development Innovations, LLC | P3 | BB |
| Encorafenib | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | P3 | BB |
+42 more in the Colon Carcinoma cohort
Other indications for Cetuximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colon Adenocarcinoma | — | P3 | BB · 70 |
| Rectal Carcinoma | — | P2 | BB · 69 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cetuximab in Colon Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cetuximab-colon-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →